216 related articles for article (PubMed ID: 14521600)
21. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
22. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
[TBL] [Abstract][Full Text] [Related]
23. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.
Migita K; Bito S; Nakamura M; Miyata S; Saito M; Kakizaki H; Nakayama Y; Matsusita T; Furuichi I; Sasazaki Y; Tanaka T; Yoshida M; Kaneko H; Abe I; Mine T; Ihara K; Kuratsu S; Saisho K; Miyahara H; Segata T; Nakagawa Y; Kamei M; Torigoshi T; Motokawa S
Arthritis Res Ther; 2014 Jul; 16(4):R154. PubMed ID: 25047862
[TBL] [Abstract][Full Text] [Related]
25. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
Doggrell SA
Expert Opin Pharmacother; 2002 Apr; 3(4):455-7. PubMed ID: 11934350
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
[TBL] [Abstract][Full Text] [Related]
27. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
29. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
30. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Turpie AG
Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
[TBL] [Abstract][Full Text] [Related]
31. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
[TBL] [Abstract][Full Text] [Related]
33. Fondaparinux for post-operative venous thrombosis prophylaxis.
Garces K
Issues Emerg Health Technol; 2002 Aug; (37):1-4. PubMed ID: 12195605
[TBL] [Abstract][Full Text] [Related]
34. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
[TBL] [Abstract][Full Text] [Related]
35. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty.
Spruill WJ; Wade WE; Leslie RB
Am J Ther; 2004; 11(1):3-8. PubMed ID: 14704589
[TBL] [Abstract][Full Text] [Related]
36. Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review.
Rashki Kemmak A; Abutorabi A; Alipour V
Clin Drug Investig; 2020 Aug; 40(8):715-725. PubMed ID: 32578155
[TBL] [Abstract][Full Text] [Related]
37. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
Wade WE; Spruill WJ; Leslie RB
Am J Orthop (Belle Mead NJ); 2003 Apr; 32(4):201-5. PubMed ID: 12723772
[TBL] [Abstract][Full Text] [Related]
38. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
[TBL] [Abstract][Full Text] [Related]
39. Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.
Lobo BL
Pharmacotherapy; 2004 Jul; 24(7 Pt 2):66S-72S. PubMed ID: 15317401
[TBL] [Abstract][Full Text] [Related]
40. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Schiff RL; Kahn SR; Shrier I; Strulovitch C; Hammouda W; Cohen E; Zukor D
Chest; 2005 Nov; 128(5):3364-71. PubMed ID: 16304285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
